NCT06630624View on ClinicalTrials.gov

Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

August 1, 2029

Study Completion Date

August 1, 2031

Conditions
Colorectal CancerLiver MetastasesLiver Metastasis Colon Cancer
Interventions
DRUG

IP-001

Intra-tumoral injection of IP-001 following ablation (MWA or IRE).

Trial Locations (1)

1118 HV

RECRUITING

Amsterdam UMC - location VUmc, Amsterdam

Sponsors
All Listed Sponsors
collaborator

Immunophotonics, Inc.

INDUSTRY

collaborator

Angiodynamics, Inc.

INDUSTRY

lead

M.R. Meijerink

OTHER

NCT06630624 - Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM | Biotech Hunter | Biotech Hunter